NCT06429150
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
RecruitingPHASE1PHASE2
Study summary
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
At a glance
- Conditions
- Multiple Myeloma, Plasmacytoma
- Interventions
- CAR-T cells
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Target enrollment
- 20 participants
- Age
- 18 Years – 80 Years
- Sex
- ALL
- Locations
- Shenzhen Geno-immune Medical Institute
- Registry
- View on ClinicalTrials.gov ↗
Eligibility criteria
Inclusion Criteria:
* Male and female subjects with multiple myeloma or plasmacytoma
* Strictly complete remission (sCR) is a treatment goal
* Expected survival \> 12 weeks
* After prior auto-SCT is eligible regardless of other prior therapies
* Adequate venous access for apheresis, and no other contraindications for leukapheresis
* Voluntary informed consent is given and commitment to continued follow-up
Exclusion Criteria:
* Pregnant or lactating women
* Uncontrolled active infection
* Active HIV, hepatitis B or hepatitis C infection
* Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
* Any medical conditions that may preclude participation